Drinkable arthritis agents to need more time to settle in market

Published: 2016-09-09 14:20:57

Updated: 2016-09-09 14:20:57

It seems the ‘drinkable arthritis treatment’ which recently landed in Korea needs more time to settle in the market. Its sales were only less than KRW 500 million in the first half of the year.

According to the pharmaceutical industry on the 7^th, Dongkook Pharmaceutical’s ‘Masibone Soln’ launched last October recorded KRW 365.15 million sales(IMS Health data).

Ahngook Pharm’s ‘Binosto’ launch...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.